These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11026031)

  • 1. [Epidermal growth factor receptor as a prognostic factor of breast cancers].
    Tsutsui S
    Nihon Rinsho; 2000 Apr; 58 Suppl():442-7. PubMed ID: 11026031
    [No Abstract]   [Full Text] [Related]  

  • 2. [An aggressive subtype of breast carcinoma].
    Dauplat MM; Mishellany F; Delatour M; Penault-Llorca F
    Ann Pathol; 2003 Dec; 23(6):611-2. PubMed ID: 15094600
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic factors for breast cancer and their use in the clinical setting.
    Kapoor A; Vogel VG
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):269-81. PubMed ID: 15877524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors.
    Pirinen R; Lipponen P; Syrjänen K
    Anticancer Res; 1995; 15(6B):2835-40. PubMed ID: 8669874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay.
    Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
    Jpn J Clin Oncol; 1994 Apr; 24(2):74-8. PubMed ID: 7908994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas. An immunohistochemical study.
    Martinazzi M; Crivelli F; Zampatti C; Martinazzi S
    Pathologica; 1993; 85(1100):637-44. PubMed ID: 8170712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.
    Göhring UJ; Ahr A; Scharl A; Weisner V; Neuhaus W; Crombach G; Holt JA
    J Soc Gynecol Investig; 1995; 2(4):653-9. PubMed ID: 9420872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
    Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
    Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of hormone sensitivity for breast cancers.
    Miyoshi Y; Murase K; Saito M; Oh K
    Breast Cancer; 2010 Apr; 17(2):86-91. PubMed ID: 19806427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic factors in breast cancer patients].
    Roisman I; Peretz T; Reznick AZ; Lifshitz I; Bitterman A; Fares F; Toledano H; Barzilay A; Durst AL
    Harefuah; 1996 May; 130(10):693-9. PubMed ID: 8794662
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmaceutical therapy of breast cancer].
    Láng I; Kahán Z; Pintér T; Dank M; Boér K; Pajkos G; Faluhelyi Z; Pikó B; Eckhardt S; Horváth Z
    Magy Onkol; 2010 Sep; 54(3):237-54. PubMed ID: 20870601
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Estrogen and progesterone receptors in breast cancer].
    Sonoo H
    Nihon Rinsho; 2000 Apr; 58 Suppl():146-53. PubMed ID: 11025988
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolution of knowledge related to breast cancer heterogeneity: a 25-year retrospective.
    Fisher B; Redmond CK; Fisher ER
    J Clin Oncol; 2008 May; 26(13):2068-71. PubMed ID: 18445835
    [No Abstract]   [Full Text] [Related]  

  • 19. Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma.
    Bacus SS; Ruby SG
    Pathol Annu; 1993; 28 Pt 1():179-204. PubMed ID: 8093211
    [No Abstract]   [Full Text] [Related]  

  • 20. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.